Trek Financial’s AstraZeneca AZN Stock Holding History

Trek Financial’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,620	Closed	-$298K	–	483
2025 Q4	$298K	Buy	1,620 +233	+17%	+$40.9K	0.02%	368
2025 Q3	$213K	Buy	+1,387	New	+$210K	0.01%	408

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Trek Financial's AZN Position: Q1 2026 in Review

Trek Financial sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,620 shares — an estimated $298K sold.

Trek Financial first reported a position in AZN in Q3 2025 and held it in 2 quarters. The position peaked at $298K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Trek Financial reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Trek Financial sold 1,620 AstraZeneca shares in Q1 2026, an estimated $298K.
Trek Financial first reported a position in AstraZeneca in Q3 2025 and held it in 2 quarters.
Trek Financial's AstraZeneca position peaked at $298K in Q4 2025.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Trek Financial's 13F filing for Q1 2026, filed 13 May 2026.